StreetInsider.com News Articles

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Mon, 10 Aug 2026 16:12:00 -0400

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.
Virtue pivotal trial is advancing with further site activations and patient enrollments.
$110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.
Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both

Piper Sandler Reiterates Neutral Rating on Medtronic, Inc. (MDT)

Mon, 10 Aug 2026 08:48:42 -0400

Piper Sandler analyst Matt O'Brien reiterated a Neutral rating and $85.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst commented: "RDN Private Payer Coverage Growing, But Meaningful Traction Still Needed; Commercial reimbursement is a critical catalyst for driving an inflection in renal denervation (RDN) adoption. Our analysis of the largest private insurers indicates that coverage remains limited, with many still classifying RDN as investigational. However, state-level analysis reveals a slightly more promising picture as select Blue Cross Blue Shield (BCBS) policies have begun implementing RDN coverage policies. We estimate that about 55% of the renal denervation population currently has reimbursement

Medtronic gets CE Mark expansion for Sphere-9 ventricular ablation

Thu, 06 Aug 2026 07:00:19 -0400

Medtronic (NYSE: MDT) announced an expanded CE Mark indication for its Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs).

According to a company statement, the Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter to receive CE Mark for ventricular ablation. The device combines pulsed field and radiofrequency ablation with high-definition mapping in a single catheter.

The U.S. Food and Drug Administration has also granted Breakthrough Device Designation for the Sphere-9 catheter for ventricular arrhythmia treatment, providing an expedited regulatory review pathway. Medtronic said the

Medtronic gets CE Mark expansion for Sphere-9 ventricular ablation

Thu, 06 Aug 2026 07:00:19 -0400

Medtronic (NYSE: MDT) announced an expanded CE Mark indication for its Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs).

According to a company statement, the Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter to receive CE Mark for ventricular ablation. The device combines pulsed field and radiofrequency ablation with high-definition mapping in a single catheter.

The U.S. Food and Drug Administration has also granted Breakthrough Device Designation for the Sphere-9 catheter for ventricular arrhythmia treatment, providing an expedited regulatory review pathway. Medtronic said the

Medtronic gets CE Mark expansion for Sphere-9 ventricular ablation

Thu, 06 Aug 2026 07:00:19 -0400

Medtronic (NYSE: MDT) announced an expanded CE Mark indication for its Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs).

According to a company statement, the Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter to receive CE Mark for ventricular ablation. The device combines pulsed field and radiofrequency ablation with high-definition mapping in a single catheter.

The U.S. Food and Drug Administration has also granted Breakthrough Device Designation for the Sphere-9 catheter for ventricular arrhythmia treatment, providing an expedited regulatory review pathway. Medtronic said the

Medtronic gets CE Mark expansion for Sphere-9 ventricular ablation

Thu, 06 Aug 2026 07:00:19 -0400

Medtronic (NYSE: MDT) announced an expanded CE Mark indication for its Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs).

According to a company statement, the Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter to receive CE Mark for ventricular ablation. The device combines pulsed field and radiofrequency ablation with high-definition mapping in a single catheter.

The U.S. Food and Drug Administration has also granted Breakthrough Device Designation for the Sphere-9 catheter for ventricular arrhythmia treatment, providing an expedited regulatory review pathway. Medtronic said the

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Thu, 06 Aug 2026 07:00:00 -0400

Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular